Korea's Ligachem partner wins FDA orphan, fast track for dual sarcoma ADC

LigaChem Biosciences' partner Sotio Biotech's ADC candidate SOT106 received FDA orphan drug designation for soft tissue sarcoma and fast track designation for osteosarcoma, facilitating regulatory development and shortening timelines for these rare cancers.

This Wire brief sits within Fusion42's coverage of Biotech.